Efficacy of Homocysteine-Lowering Therapy With Folic Acid in Stroke Prevention: A Meta-Analysis

Stroke
Q1
Jun 2010
Citations:150
Influential Citations:2
Systematic Reviews / Meta-Analyses
80
S2 IconPDF Icon

Enhanced Details

Methods
Design: randomized controlled trials (RCTs). Participants: adults at high cardiovascular risk with pre-existing conditions (including prior stroke, coronary heart disease, manifest cardiovascular disease or multiple risk factors, end-stage renal disease/advanced CKD, esophageal dysplasia); both genders; age range not specified. 13 RCTs enrolling 39,005 individuals.
Intervention
Folic acid supplementation (with or without vitamins B6 and B12) for at least 6 months.
Results
Overall, folic acid supplementation did not significantly reduce stroke risk (RR 0.93, 95% CI 0.85-1.03; p=0.16). In nonsecondary-prevention trials, RR 0.89 (95% CI 0.79-0.99; p=0.03). In trials with folic acid plus vitamins B6 and B12, RR 0.83 (95% CI 0.71-0.97; p=0.02). In men-predominant trials, RR 0.84 (95% CI 0.74-0.94; p=0.003). Longer treatment duration (≥3 years) and larger homocysteine reductions (≥20%) also associated with lower stroke, but meta-regression did not show a linear dose-response (p=0.73 and p=0.77). Conclusion: No major stroke-prevention benefit overall; mild, context-specific benefits warrant further investigation.
Limitations
Meta-analysis is retrospective; potential search incompleteness and publication bias; heterogeneity in trial populations, interventions, outcome definitions, and stroke adjudication; background folic acid fortification may dilute treatment effects; multiplicity of subgroup analyses limits interpretability; insufficient data to establish dose-response relationships.

Abstract

Background and Purpose— Although a lower serum homocysteine concentration is associated with a reduced risk of stroke in epidemiologic studies, randomized, controlled trials have yielded mixed findings regarding the effect of therapeutic homocysteine...